OBJECTIVE: The link between CNS penetration of antiretrovirals and AIDS-defining neurologic disorders remains largely unknown. METHODS: HIV-infected, antiretroviral therapy-naive individuals in the HIV-CAUSAL Collaboration who started an antiretroviral regimen were classified according to the CNS Penetration Effectiveness (CPE) score of their initial regimen into low (<8), medium (8-9), or high (>9) CPE score. We estimated "intention-to-treat" hazard ratios of 4 neuroAIDS conditions for baseline regimens with high and medium CPE scores compared with regimens with a low score. We used inverse probability weighting to adjust for potential bias due to infrequent follow-up. RESULTS: A total of 61,938 individuals were followed for a median (interquartile range) of 37 (18, 70) months. During follow-up, there were 235 cases of HIV dementia, 169 cases of toxoplasmosis, 128 cases of cryptococcal meningitis, and 141 cases of progressive multifocal leukoencephalopathy. The hazard ratio (95% confidence interval) for initiating a combined antiretroviral therapy regimen with a high vs low CPE score was 1.74 (1.15, 2.65) for HIV dementia, 0.90 (0.50, 1.62) for toxoplasmosis, 1.13 (0.61, 2.11) for cryptococcal meningitis, and 1.32 (0.71, 2.47) for progressive multifocal leukoencephalopathy. The respective hazard ratios (95% confidence intervals) for a medium vs low CPE score were 1.01 (0.73, 1.39), 0.80 (0.56, 1.15), 1.08 (0.73, 1.62), and 1.08 (0.73, 1.58). CONCLUSIONS: We estimated that initiation of a combined antiretroviral therapy regimen with a high CPE score increases the risk of HIV dementia, but not of other neuroAIDS conditions.
OBJECTIVE: The link between CNS penetration of antiretrovirals and AIDS-defining neurologic disorders remains largely unknown. METHODS: HIV-infected, antiretroviral therapy-naive individuals in the HIV-CAUSAL Collaboration who started an antiretroviral regimen were classified according to the CNS Penetration Effectiveness (CPE) score of their initial regimen into low (<8), medium (8-9), or high (>9) CPE score. We estimated "intention-to-treat" hazard ratios of 4 neuroAIDS conditions for baseline regimens with high and medium CPE scores compared with regimens with a low score. We used inverse probability weighting to adjust for potential bias due to infrequent follow-up. RESULTS: A total of 61,938 individuals were followed for a median (interquartile range) of 37 (18, 70) months. During follow-up, there were 235 cases of HIV dementia, 169 cases of toxoplasmosis, 128 cases of cryptococcal meningitis, and 141 cases of progressive multifocal leukoencephalopathy. The hazard ratio (95% confidence interval) for initiating a combined antiretroviral therapy regimen with a high vs low CPE score was 1.74 (1.15, 2.65) for HIV dementia, 0.90 (0.50, 1.62) for toxoplasmosis, 1.13 (0.61, 2.11) for cryptococcal meningitis, and 1.32 (0.71, 2.47) for progressive multifocal leukoencephalopathy. The respective hazard ratios (95% confidence intervals) for a medium vs low CPE score were 1.01 (0.73, 1.39), 0.80 (0.56, 1.15), 1.08 (0.73, 1.62), and 1.08 (0.73, 1.58). CONCLUSIONS: We estimated that initiation of a combined antiretroviral therapy regimen with a high CPE score increases the risk of HIV dementia, but not of other neuroAIDS conditions.
Authors: Alexia Cusini; Pietro L Vernazza; Sabine Yerly; Laurent A Decosterd; Bruno Ledergerber; Christoph A Fux; Janine Rohrbach; Nicolas Widmer; Bernhard Hirschel; Roman Gaudenz; Matthias Cavassini; Thomas Klimkait; Franziska Zenger; Chistine Gutmann; Milos Opravil; Huldyrich F Günthard Journal: J Acquir Immune Defic Syndr Date: 2013-01-01 Impact factor: 3.731
Authors: R K Heaton; D B Clifford; D R Franklin; S P Woods; C Ake; F Vaida; R J Ellis; S L Letendre; T D Marcotte; J H Atkinson; M Rivera-Mindt; O R Vigil; M J Taylor; A C Collier; C M Marra; B B Gelman; J C McArthur; S Morgello; D M Simpson; J A McCutchan; I Abramson; A Gamst; C Fennema-Notestine; T L Jernigan; J Wong; I Grant Journal: Neurology Date: 2010-12-07 Impact factor: 9.910
Authors: Jonathan A C Sterne; Miguel A Hernán; Bruno Ledergerber; Kate Tilling; Rainer Weber; Pedram Sendi; Martin Rickenbach; James M Robins; Matthias Egger Journal: Lancet Date: 2005 Jul 30-Aug 5 Impact factor: 79.321
Authors: Brian Giunta; Jared Ehrhart; Demian F Obregon; Lucy Lam; Lisa Le; JingJi Jin; Francisco Fernandez; Jun Tan; R Douglas Shytle Journal: Mol Brain Date: 2011-06-07 Impact factor: 4.041
Authors: Janet P Tate; Amy C Justice; Michael D Hughes; Fabrice Bonnet; Peter Reiss; Amanda Mocroft; Jacob Nattermann; Fiona C Lampe; Heiner C Bucher; Timothy R Sterling; Heidi M Crane; Mari M Kitahata; Margaret May; Jonathan A C Sterne Journal: AIDS Date: 2013-02-20 Impact factor: 4.177
Authors: Alicia McFarren; Lillie Lopez; Dionna W Williams; Mike Veenstra; Ruth A Bryan; Aliza Goldsmith; Alfred Morgenstern; Frank Bruchertseifer; Susan Zolla-Pazner; Miroslaw K Gorny; Eliseo A Eugenin; Joan W Berman; Ekaterina Dadachova Journal: AIDS Date: 2016-02-20 Impact factor: 4.177
Authors: Laurie M Baker; Robert H Paul; Jodi M Heaps-Woodruff; Jee Yoon Chang; Mario Ortega; Zachary Margolin; Christina Usher; Brian Basco; Sarah Cooley; Beau M Ances Journal: J Neuroimmune Pharmacol Date: 2015-04-22 Impact factor: 4.147
Authors: Nathan A Summers; Colleen F Kelley; Wendy Armstrong; Vincent C Marconi; Minh Ly Nguyen Journal: AIDS Res Hum Retroviruses Date: 2019-04-03 Impact factor: 2.205